GeneTex Launches New Antibody Against Phosphorylated Histone H3 For Epigenetics Research
IRVINE, Calif., Dec. 10, 2012 /PRNewswire/ -- GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody against phosphorylated Histone H3. Histone proteins package and organize the DNA of eukaryotic cells into structural units referred to as nucleosomes, and the modification of histone tails plays a critical role in the modulation of gene transcription.
The phosphorylation of Histone H3 at serine residue 10 by Msk1 during interphase marks transcriptional activation. Aurora kinase B also phosphorylates Ser10, along with Ser28, at the onset of mitosis to initiate chromosome condensation. More recent evidence suggests that the phosphorylation of Histone H3 at Ser10 stimulates Lys14 acetylation and may also act as a "master switch" that prevents the abnormal phosphorylation of Histone H3 at other sites during mitosis.GeneTex's new Histone H3 (phospho Ser10) antibody will allow researchers to further examine the role that histone phosphorylation plays in complex epigenetic processes. The antibody has been validated for western blotting in both human and mouse samples as well as for immunocytochemistry/immunofluorescence. For additional information on GeneTex, Inc. and its epigenetics antibodies, please call toll-free 877-GENETEX (436-3839) or visit www.genetex.com. About GeneTex, Inc. GeneTex, Inc. is an antibody company founded in 1997 by a group of internationally renowned scientists from academia. They strive to produce the highest quality antibodies and reagents. Their primary and secondary antibodies are created through a process involving extensive research, development and validation. GeneTex's catalog has grown to over 55,000 primary antibodies and all are backed by a 100% Satisfaction Guarantee. Corporate Mission We strive to serve and accelerate life science research by creating essential life science tools where quality can be found in every vial.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV